Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.41 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29719180 | 1.00 | EGFR (0.41) | EGFRENPP1PDE4APDE4BPDE4C | |
| SCHEMBL30275314 | 0.83 | EGFR (0.54) | EGFRENPP1PDE4APDE4BPDE4C | |
| SCHEMBL1469486 | 0.83 | EGFR (0.54) | EGFRENPP1PDE4APDE4BPDE4C | |
| SCHEMBL22983920 | 0.83 | ABCG2 (0.38) | EGFRABCG2PARP1 | |
| SCHEMBL2997470 | 0.82 | EGFR (0.50) | EGFRENPP1PDE4APDE4BPDE4C | |
| SCHEMBL25409 | 0.81 | EGFR (0.41) | EGFRENPP1PDE4APDE4BPDE4C | |
| SCHEMBL14579636 | 0.81 | GAA (0.43) | EGFRENPP1PDE4APDE4BPDE4C | |
| SCHEMBL12488021 | 0.81 | EGFR (0.46) | EGFRENPP1PDE4APDE4BPDE4C | |
| SCHEMBL29719028 | 0.81 | EGFR (0.41) | EGFRENPP1PDE4APDE4BPDE4C | |
| SCHEMBL20127277 | 0.81 | EGFR (0.52) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079960-A | Alkynyl quinazoline compounds | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4013749-B1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260049063-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12435046-B2 | Alkynyl quinazoline compounds | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| CN-119390683-A | Alkynyl quinazoline compounds | 黑钻治疗公司 | 2025-02-07 | — | — | CN | disclosed |
| US-20220298120-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS, INC. | 2022-09-22 | — | — | US | disclosed |
| CN-114787150-A | Alkynyl quinazoline compounds | 黑钻治疗公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-4013749-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | Black Diamond Therapeutics, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| WO-2021030711-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435046-B2 | Alkynyl quinazoline compounds | GLS, GLS2, MCL1 | EGFR 677/4885ENPP1 1450/4885PDE4A 1499/4885 |
| US-20220298120-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | GLS, GLS2, MCL1 | EGFR 677/4885ENPP1 1450/4885PDE4A 1499/4885 |
| US-20260049063-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, BCL6 | EGFR 324/4885ENPP1 2695/4885PDE4A 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.